Ropes & Gray represented ImmunoGen in its sale to AbbVie, which will acquire ImmunoGen, and its flagship cancer therapy ELAHERE®. Under the terms of the transaction, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion. The transaction was announced in a press release on November 30.
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer.
The deal team was led by mergers & acquisitions partner Tara Fisher, executive compensation & employee benefits partner Renata Ferrari, litigation & enforcement partners Mike McFalls and Ruchit Patel, IP transactions partner David McIntosh, finance partner Dan Coyne, tax partner David Saltzman and corporate associate Tyler Silvey.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
